Acute Kidney Injury Due to Sepsis Clinical Trial
Official title:
Comparison of Plasma Neutrophil Gelatinase-Associated Lipocalin (pNGAL) Level in De-Resuscitation With Furosemide Group and Control Group as a Predictor of Sepsis in Acute Kidney Injury Patients in the ICU Within 48 Hours of Treatment
The impact of early de-resuscitation with furosemide on patients with sepsis-related acute kidney injury using pNGAL as the parameter of acute kidney injury.
Sepsis-related acute kidney injury (SAKI) is a complication leading to morbidity and mortality in septic patients. Some 50% of AKI patients in the Intensive Care Unit (ICU) are sepsis patients, which is the highest cause of death in the ICU. In sepsis, there is systemic inflammation that causes endothelial damage, which manifests in capillary leakage. Fluid accumulation that has occurred since the patient came to the hospital due to a capillary leak in sepsis and is exacerbated by fluid resuscitation has a negative impact on the kidneys. Therefore, the aim of this study was to assess the effectiveness of early de-resuscitation using furosemide on the incidence of AKI in septic patients using pNGAL as a parameter of AKI. This study used a double-blind, randomized clinical trial design. This study was conducted on septic patients with a cumulative balance of >1500 mL/day and urine output of 0.8 cc/kg/hour in the ICU of Dr. Cipto Mangunkusumo National Central Public Hospital in the July-December 2023 period. pNGAL levels were checked at the 0th and 48th hours of ICU care. A total of 48 subjects were divided into 2 groups: 24 patients in the treatment group were given a continuous injection of furosemide at 2 mg/hour, and 24 patients in the control group were given a placebo injection at 2 mg/hour. The patient's condition will be followed after the ICU stay for up to 28 days to record the need for renal replacement therapy and death. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05114057 -
Use of NGAL for Fluid Dosing and CRRT Initiation in Pediatric and Neonatal AKI
|
N/A | |
Completed |
NCT05507437 -
Pharmacokinetics and Safety of TIN816 in Patients With Sepsis-associated Acute Kidney Injury
|
Phase 2 | |
Terminated |
NCT04411472 -
(Revival) Study to Investigate the Efficacy and Safety of Alkaline Phosphatase in Patients With Sepsis-Associated AKI
|
Phase 3 | |
Recruiting |
NCT06295393 -
Renin Angiotensin Aldosterone System In Septic Kids
|
||
Completed |
NCT04633746 -
Plasma Endostatin Predicts Outcome of Septic AKI
|
||
Recruiting |
NCT05996835 -
Phase 2b Study to Investigate the Safety and Efficacy of TIN816 in Sepsis-associated Acute Kidney Injury (SA-AKI)
|
Phase 2 | |
Recruiting |
NCT05575024 -
Hemodynamic Stability in Septic Shock Patients Undergoing Continuous Renal Replacement Therapy With oXiris Membrane
|
||
Completed |
NCT05060679 -
Presepsin:Gelsolin Ratio in Sepsis-related Organ Dysfunction
|
||
Completed |
NCT04968262 -
Urinary Actin, as a Potential Marker of Sepsis-related Acute Kidney Injury
|
||
Not yet recruiting |
NCT05559086 -
N/LP Ratio as Predictor of Mortality in Septic AKI Patients
|
||
Recruiting |
NCT05982340 -
Endogenous Lithium Clearance in Acute Kidney Injury
|